title: Parenchymal sparing surgery for central renal tumors in patients with hereditary renal cancers.
abstract: OBJECTIVE
  Nephron sparing surgery has become accepted surgical practice for removing of renal tumors. The resection of central lesions has been thought to be more surgically challenging than that of peripheral tumors. We analyzed our experience with renal preservation surgery in patients with small hereditary central renal tumors.
  
  
  METHODS
  From 1992 to 2000 we performed 116 partial nephrectomies with 44 kidneys (38%) demonstrating central renal masses. Central renal tumors were defined radiologically as those completely encircled by parenchyma or transgressing the interpapillary line on computerized tomography. We compared this group to a similar series of 67 patients with hereditary renal cancer with only peripheral based tumors.
  
  
  RESULTS
  Mean tumor size was 3.2 cm (range 1.5 to 7.5). Mean operative time was 352 minutes (range 70 to 830). Renal hypothermia and vascular clamping were used in 19 of 44 procedures (41%). Mean ischemic time was 55 minutes (range 16 to 143). Mean blood loss was 4.6 l (range 0.1 to 23). The complication rate was 23% (10 of 44 cases) and with 18% (8 of 44) directly related to surgical technique. The mean transfusion requirement was 6.7 U (range 0 to 32) and 12 of 44 procedures (27%) required no blood products. Mean preoperative and postoperative serum creatinine was 1.05 (range 0.6 to 1.8) and 1.08 mg/dl (range 0.6 to 2.1), respectively. Mean followup was 33.7 months. No metastasis developed during followup.
  
  
  CONCLUSIONS
  Central renal tumors are a common manifestation of hereditary renal cell carcinoma. There was no statistical difference found between common operative parameters when central and peripheral nephron sparing surgeries were compared. However, mean operative blood loss and transfusion requirements were increased in the central tumor group.
authors.affiliation: Urologic Oncology Branch and Diagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Darrel E
authors.initials: DE
authors.lastname: Drachenberg
authors.forename: Othon J
authors.initials: OJ
authors.lastname: Mena
authors.forename: Peter L
authors.initials: PL
authors.lastname: Choyke
authors.forename: W Marston
authors.initials: WM
authors.lastname: Linehan
authors.forename: McClellan M
authors.initials: MM
authors.lastname: Walther
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016063:Blood Loss, Surgical; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007036:Hypothermia, Induced; D007680:Kidney Neoplasms / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009392:Nephrectomy / Q000379:methods*; D012189:Retrospective Studies
chemical_list: D003404:Creatinine